Identification of CD318 (CDCP1) as novel prognostic marker in AML
JS Heitmann, I Hagelstein, C Hinterleitner… - Annals of …, 2020 - Springer
Genetic and morphological markers are well-established prognostic factors in acute myeloid
leukemia (AML). However, further reliable markers are urgently needed to improve risk …
leukemia (AML). However, further reliable markers are urgently needed to improve risk …
CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease
MP Scolnik, R Morilla, MME de Bracco, D Catovsky… - Leukemia research, 2002 - Elsevier
We estimated by quantitative flow cytometry (FC) the expression of CD13, CD33, CD34 and
CD117 antigens in cells from 64 patients with acute myeloid leukaemia (AML) and 22 …
CD117 antigens in cells from 64 patients with acute myeloid leukaemia (AML) and 22 …
CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin
HJ Bühring, S Kuçi, T Conze, G Rathke, K Bartolović… - Stem …, 2004 - academic.oup.com
Abstract CUB‐domain‐containing protein 1 (CDCP1) is a novel transmembrane molecule
that is expressed in metastatic colon and breast tumors as well as on the surface of …
that is expressed in metastatic colon and breast tumors as well as on the surface of …
Dysregulation of circulating CDC42 and its correlation with demographic characteristics, comorbidities, tumor features, chemotherapeutic regimen and survival profile …
J Yan, D Wan - Journal of Clinical Laboratory Analysis, 2022 - Wiley Online Library
Objective Cell division control protein 42 (CDC42) induces the immune escape, represses
the CD8+ T‐cell activation, and further leads to the tumor metastasis in various neoplasms …
the CD8+ T‐cell activation, and further leads to the tumor metastasis in various neoplasms …
CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors
AK Brenner, H Reikvam, KP Rye, KM Hagen… - Molecules, 2017 - mdpi.com
Cell division cycle 25 (CDC25) protein phosphatases regulate cell cycle progression
through the activation of cyclin-dependent kinases (CDKs), but they are also involved in …
through the activation of cyclin-dependent kinases (CDKs), but they are also involved in …
Novel biomarker proteins in chronic lymphocytic leukemia: impact on diagnosis, prognosis and treatment
L Admoni-Elisha, I Nakdimon, A Shteinfer, T Prezma… - PLoS …, 2016 - journals.plos.org
In many cancers, cells undergo re-programming of metabolism, cell survival and anti-
apoptotic defense strategies, with the proteins mediating this reprogramming representing …
apoptotic defense strategies, with the proteins mediating this reprogramming representing …
Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis
J Juncà, M Garcia-Caro, I Granada… - Annals of …, 2014 - Springer
Among other phenotypic markers, CD11b expression has been considered as an
unfavorable prognostic factor, both in terms of overall survival (OS), disease-free survival …
unfavorable prognostic factor, both in terms of overall survival (OS), disease-free survival …
The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients
S Gao, J Xue, X Wu, T Zhong… - Journal of Clinical …, 2022 - Wiley Online Library
Background Cell division control protein 42 (CDC42) is involved in colorectal cancer (CRC)
progression by modulating CD8+ T cell activation, immune escape, and direct oncogenetic …
progression by modulating CD8+ T cell activation, immune escape, and direct oncogenetic …
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients
M Gentile, TD Shanafelt, D Rossi… - Blood, The Journal …, 2016 - ashpublications.org
Recently, an international collaboration collected information from; 3500 chronic lymphocytic
leukemia (CLL) patients to develop a comprehensive tool for predicting overall survival …
leukemia (CLL) patients to develop a comprehensive tool for predicting overall survival …
Over-expression of CD200 predicts poor prognosis in MDS
J Chen, L Mei, B Chen, D Wang, L Luo, R Lu… - Leukemia Research, 2017 - Elsevier
Background We studied the expression of CD200 in a series of 101 patients with diagnosis
of myelodysplastic syndrome (MDS), to evaluate its impact on outcome and its possible …
of myelodysplastic syndrome (MDS), to evaluate its impact on outcome and its possible …